SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Recruiting now

Conditions studied: Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes

In brief

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Key facts

Study ID

NCT03452774

Run by

Massive Bio, Inc.

People needed

50000

Starts

2018-01-01

Expected to finish

2040-06-01

Last updated by the study team

2025-10-28

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pts with solid and hematological malignancies;
• Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.
• These biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform
• Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient

You may not qualify if…

• ECOG PS > 2;
• Abnormal organ function;
• Hospice enrollment

Where it is running

• Massive Bio SYNERGY-AI site — Mobile, Alabama, United States (enrolling)
• Massive Bio SYNERGY-AI site — Scottsdale, Arizona, United States (enrolling)
• Massive Bio SYNERGY-AI site — Little Rock, Arkansas, United States (enrolling)
• Massive Bio SYNERGY-AI site — Duarte, California, United States (enrolling)
• Massive Bio SYNERGY-AI site — Irvine, California, United States (enrolling)
• Massive Bio SYNERGY-AI site — La Jolla, California, United States (enrolling)
• Massive Bio SYNERGY-AI site — Orange, California, United States (enrolling)
• Massive Bio SYNERGY-AI site — San Francisco, California, United States (enrolling)
• Massive Bio SYNERGY-AI site — Stanford, California, United States (enrolling)
• Massive Bio SYNERGY-AI site — Aurora, Colorado, United States (enrolling)
• Massive Bio SYNERGY-AI site — Denver, Colorado, United States (enrolling)
• Massive Bio SYNERGY-AI site — Littleton, Colorado, United States (enrolling)
• Massive Bio SYNERGY-AI site — Hartford, Connecticut, United States (enrolling)
• Massive Bio SYNERGY-AI site — Norwalk, Connecticut, United States (enrolling)
• Massive Bio SYNERGY-AI site — Newark, Delaware, United States (enrolling)
• Massive Bio SYNERGY-AI site — Jacksonville, Florida, United States (enrolling)
• Massive Bio SYNERGY-AI site — Miami, Florida, United States (enrolling)
• Massive Bio SYNERGY-AI site — Tampa, Florida, United States (enrolling)
• Massive Bio SYNERGY-AI site — Atlanta, Georgia, United States (enrolling)
• Massive Bio SYNERGY-AI site — Savannah, Georgia, United States (enrolling)
• Massive Bio SYNERGY-AI site — Boise, Idaho, United States (enrolling)
• Massive Bio SYNERGY-AI site — Chicago, Illinois, United States (enrolling)
• Massive Bio SYNERGY-AI site — Iowa City, Iowa, United States (enrolling)
• Massive Bio SYNERGY-AI site — New Orleans, Louisiana, United States (enrolling)
• Massive Bio SYNERGY-AI site — Birmingham, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.